News

Jinse Finance reported that Federal Reserve's Kashkari stated that the U.S. economy does not require restrictive policies and does not want to repeat the mistake of the "transitory" misjudgment. Before the Iran war, the inflation trend was positive, but now the conflict has made the outlook for monetary policy uncertain. As the prospect is overshadowed by the threat of war, the Federal Reserve can wait and see. He also mentioned that if inflation cools down, it may be appropriate to cut interest rates once or twice later this year.

This substantial expenditure is directly related to the payment obligations of a major settlement agreement, reflecting the financial impact the company faces in resolving legal and commercial disputes. The recognition of this expense will follow the requirements of US Generally Accepted Accounting Principles (GAAP) and will have a significant effect on current profits. Analysts point out that although this provision may temporarily suppress the stock price, thoroughly resolving historical issues will help Moderna focus more on the strategic layout of its mRNA technology pipeline.

It is worth noting that this authorization includes the $500 million repurchase quota already approved by the company in June 2025. This large-scale repurchase initiative demonstrates the management's strong confidence in the company's future prospects and reflects its commitment to creating value for shareholders through capital returns. By repurchasing and canceling shares, the company is expected to increase earnings per share, thereby optimizing shareholder equity.